Tizanidine

Introduction Overview

Generic Name

tizanidine

Brand Name

Zanaflex, Ontralfy

Dosage Form

oral tablet, oral capsule, oral solution

Drug Class

skeletal muscle relaxants

Pharmacokinetics

Absorption: Tizanidine exhibits rapid and nearly complete absorption following oral administration, with peak plasma concentrations typically achieved within 1 to 2 hours. The presence of food affects absorption variably depending on the dosage form; administration of tizanidine tablets with food increases peak plasma levels and prolongs time to peak concentration, whereas capsules show a decrease in peak levels with food intake, delaying peak concentration time. The oral solution's pharmacokinetics are not significantly altered by food, though the drug's duration may be extended. Absorption is influenced by the formulation and presence or absence of food, emphasizing the importance of consistent administration relative to meals to avoid fluctuations in therapeutic efficacy and side effects. Distribution: Tizanidine is moderately distributed in body tissues, with an apparent volume of distribution estimated between 2.3 to 5 liters per kilogram, indicating extensive tissue uptake. It exhibits approximately 30% plasma protein binding, predominantly to albumin, which facilitates its systemic distribution. Tizanidine readily crosses the blood-brain barrier, accounting for its central muscle relaxant effects. Its affinity for central alpha-2 adrenergic receptors in the central nervous system mediates pharmacodynamic activity. Metabolism: The drug undergoes extensive first-pass hepatic metabolism largely via cytochrome P450 1A2 (CYP1A2) enzymes, resulting in the formation of less active metabolites predominantly eliminated renally. The hepatic oxidative metabolism substantially reduces systemic bioavailability to about 40%. Drug interactions influencing CYP1A2 activity, such as fluvoxamine and ciprofloxacin, can significantly elevate tizanidine plasma levels and increase risk for toxicity. Consequently, these inhibitors are contraindicated concomitantly. Genetic polymorphisms and hepatic function status may also alter metabolic clearance. Elimination: Tizanidine and its metabolites are principally eliminated via renal excretion, with an elimination half-life averaging approximately 2.5 hours, underlying its short-acting profile. The majority of administered dose (>75%) is recovered as metabolites in urine within 24 hours, with minimal unchanged drug excreted. Renal impairment can reduce clearance, necessitating dosage adjustments to prevent toxicity. The relatively short half-life mandates administration multiple times per day for sustained spasticity control. Slow or impaired elimination prolongs half-life and heightens adverse effect risk. Regular liver and renal function monitoring is advised during therapy to adjust dosing appropriately and minimize adverse outcomes.

Dosage Forms

Available Dosage Forms: Tizanidine is available in several oral formulations to accommodate patient preferences and clinical requirements. These include oral tablets (commonly 2 mg and 4 mg strengths), oral capsules, and an oral solution formulation offered as 2 mg per 5 mL for precise dosing, especially in patients with swallowing difficulties or requiring titration. The brand Ontralfy is specifically available as a 2 mg/5 mL oral solution. Dosages for Adults and Adolescents: The recommended initial dosing regimen starts at 2 mg every 6 to 8 hours, with a maximum of three doses in a 24-hour period. Titration increments are based on therapeutic response and tolerability, not exceeding a single dose of 8 mg or a total daily dose of 36 mg to reduce the risk of hepatotoxicity. Dosing frequency typically allows 6 to 8 hours between doses due to the drug's short half-life. Patients are advised to maintain consistent administration conditions relative to meals to ensure predictable pharmacokinetics. Specific Patient Populations: Dose adjustments and careful monitoring are warranted in patients with hepatic or renal impairment, given altered metabolism and elimination that could enhance drug exposure. Elderly patients may exhibit increased sensitivity and require lower starting doses. Use during pregnancy requires a risk-benefit assessment due to limited safety data. Breastfeeding may pose risks of exposure to the infant and should be discussed with healthcare providers. Pediatric safety and efficacy have not been well established, so use in this group should be cautious and under specialist guidance. The need for frequent liver function tests applies particularly to these vulnerable populations to detect early signs of hepatic damage.

Mechanism Of Action

Tizanidine's primary mechanism involves selective agonism at central alpha-2 adrenergic receptors predominantly located within the central nervous system, particularly within the spinal cord and brainstem. By stimulating these presynaptic receptors, tizanidine inhibits the release of excitatory neurotransmitters such as glutamate and substance P, thereby reducing the excitatory input to motor neurons. This leads to decreased spasticity due to attenuation of polysynaptic reflex activity. At the molecular level, binding to alpha-2 receptors decreases cyclic AMP production and downstream calcium influx, resulting in suppressed neurotransmitter release from nerve terminals. The diminished excitatory transmission translates clinically into muscle relaxation and relief of increased muscle tone associated with spasticity. Additionally, tizanidine modulates interneuronal circuits that influence muscle spindle activity, further contributing to the reduction of spasticity. Compared to other muscle relaxants, tizanidine's centrally mediated alpha-2 adrenergic agonism provides a distinct pharmacological profile that differs from agents such as baclofen (GABA-B receptor agonist) or cyclobenzaprine (presynaptic noradrenergic inhibitor). Research has demonstrated that tizanidine's precise modulation of spinal interneurons allows effective control of muscle spasticity with relatively less sedation compared to some alternatives. Clinical studies confirm its efficacy in multiple sclerosis, spinal cord injuries, and other neurological conditions characterized by increased muscle tone. While its mechanism correlates with dose-related side effects like hypotension due to central adrenergic effects, cautious titration and patient monitoring optimize therapeutic outcomes. Emerging research continues to explore its receptor binding kinetics and potential off-target effects, informing best practices for clinical use.

Pharmacological Actions

Acts as a centrally-acting alpha-2 adrenergic receptor agonist with predominant activity in the spinal cord.
Inhibits release of excitatory amino acids such as glutamate, reducing excitatory input to motor neurons.
Decreases polysynaptic reflex activity leading to muscle relaxation and reduction in spasticity.
Modulates interneuronal circuits involved in muscle spindle activity, contributing to lowered muscle tone.
Produces transient antihypertensive effects due to systemic alpha-2 adrenergic receptor stimulation.
Exerts short-acting skeletal muscle relaxant effects suitable for management of spasticity.
Does not exhibit direct peripheral muscle relaxant activity but acts via central nervous system pathways.
Induces dose-dependent sedation and dizziness related to central nervous system depressant effects.
Demonstrates efficacy in reducing muscle hypertonia in multiple sclerosis, spinal cord injury, and stroke.
Exhibits weak analgesic effects secondary to muscle relaxation and decreased reflex muscle spasm.
Has minimal potential for dependence but may cause withdrawal symptoms upon abrupt cessation.
May cause hypotension and bradycardia due to CNS-mediated autonomic effects.
Does not possess significant anticholinergic or direct neuromuscular blocking properties.
Displays a pharmacodynamic profile distinct from other muscle relaxants like baclofen and cyclobenzaprine.

Therapeutic Or Clinical Uses

Management of spasticity associated with multiple sclerosis.
Treatment of muscle spasticity following spinal cord injury.
Symptomatic relief of increased muscle tone due to cerebral palsy.
Adjunct therapy for muscle spasm linked to stroke or neurological disorders.
Used in short-term management of muscle spasticity requiring intermittent relief.
Relief of muscle stiffness and tightness secondary to neurological conditions.
Employed to improve functional mobility in patients with spastic muscle disorders.
Potential off-label use for muscle spasticity in amyotrophic lateral sclerosis (ALS).
Treatment of painful muscle spasms where centrally acting muscle relaxants are indicated.
Used to reduce muscle tone to facilitate physical therapy and rehabilitation interventions.
Considered when other muscle relaxants are contraindicated or not well tolerated.
May be used to improve quality of life by reducing disabling muscle hypertonia.

Side Or Adverse Effects

Drowsiness and sedation are common, affecting patient alertness.
Dizziness and weakness may occur, increasing fall risk especially in elderly.
Dry mouth is frequently reported due to anticholinergic-like effects.
Hypotension with potential for orthostatic dizziness or syncope.
Asthenia characterized by fatigue or generalized weakness.
Blurred vision as a central nervous system side effect.
Elevations in liver enzymes indicating possible hepatotoxicity requiring monitoring.
Confusion and hallucinations in rare cases, particularly at higher doses.
Urinary retention or painful urination has been noted.
Gastrointestinal symptoms such as nausea, vomiting, and constipation.
Runny nose and sore throat reflecting mild upper respiratory effects.
Uncontrolled muscle movements or tremors as paradoxical reactions.
Withdrawal symptoms including anxiety, tremor, and palpitations upon sudden cessation.
Allergic reactions including rash, hives, or swelling of the face or throat.
Respiratory depression is possible when combined with other CNS depressants.

Precautions

Use with caution in patients with existing liver impairment due to hepatotoxicity risk.
Initiate treatment at low doses with gradual titration to minimize hypotension and sedation.
Avoid abrupt discontinuation to prevent withdrawal symptoms; taper dosing appropriately.
Close monitoring required when co-administered with other CNS depressants or muscle relaxants.
Exercise caution in patients with renal impairment due to altered drug elimination.
Assess blood pressure regularly as tizanidine may induce clinically significant hypotension.
Use caution during activities requiring alertness, such as driving or operating machinery.
Avoid concomitant use with potent CYP1A2 inhibitors like ciprofloxacin and fluvoxamine.
Monitor liver function tests frequently, especially during dose escalation or long-term use.
Instruct patients to maintain consistent administration relative to meals to avoid variable effects.
Pregnancy and breastfeeding decisions require individualized risk-benefit considerations.
Elderly patients may be more sensitive to adverse effects and require dose adjustments.
Adjust doses carefully in patients with cardiovascular disease due to possible bradycardia.
Advise patients to avoid alcohol as it exacerbates CNS depressant effects.
Educate patients on signs of hypotension and the importance of slow position changes.

Warnings

Contraindicated with concomitant use of fluvoxamine or ciprofloxacin due to risk of severe hypotension and toxicity.
Potential for liver injury necessitates regular hepatic function monitoring during therapy.
Use only for daily activities requiring spasticity relief; avoid use when normal muscle tone is essential for safety.
Abrupt cessation after long-term use may lead to withdrawal symptoms including tremor, anxiety, and tachycardia.
May cause significant sedation and impair mental alertness; caution advised when performing hazardous tasks.
Risk of orthostatic hypotension; advise patients to rise slowly from sitting or lying positions.
Concomitant use with other CNS depressants increases risk of respiratory depression and excessive sedation.
Excessive dosing beyond recommended maximum increases risk of hepatotoxicity and adverse CNS effects.
Not a controlled substance; abuse potential is not well studied but withdrawal symptoms reported.
Use with caution in patients with low blood pressure or cardiovascular disorders.
Avoid switching between dosage forms or modifications in food intake without consulting healthcare provider.
Discontinue if signs of hypersensitivity or serious adverse reactions occur.
Use during pregnancy and breastfeeding requires medical supervision due to insufficient safety data.
Notify healthcare provider if muscle relaxant effect is insufficient or side effects worsen.
Risk-benefit assessment necessary in elderly or debilitated patients with multiple comorbidities.

Contraindication

Known hypersensitivity to tizanidine or any component of the formulation.
Concurrent use with CYP1A2 inhibitors such as fluvoxamine (Luvox) and ciprofloxacin (Cipro).
Severe hepatic impairment due to increased risk of accumulation and toxicity.
Patients with hypotension or bradycardia prone to exacerbation by alpha-2 agonists.
Avoid use in patients with spasticity requiring full muscle tone for safe ambulation or balance.
Potential allergy or previous adverse reaction to similar skeletal muscle relaxants.
Not recommended in pediatric population due to lack of safety and efficacy data.
Use contraindicated if patient unable to comply with frequent monitoring and dosing instructions.
Absolute contraindication in patients with known interactions causing life-threatening hypotension.
Patients with respiratory depression or compromised respiratory function should avoid tizanidine.

Drug Interactions

Cytochrome P450 1A2 inhibitors such as fluvoxamine sharply increase tizanidine plasma levels, leading to toxicity.
Ciprofloxacin and other fluoroquinolone antibiotics inhibit CYP1A2, causing dangerously elevated tizanidine concentrations.
Concurrent use with antihypertensives like clonidine, guanfacine, or methyldopa may enhance hypotensive effects.
Heart rhythm medications including amiodarone, mexiletine, propafenone, and verapamil may potentiate bradycardia or hypotension.
Stomach acid suppressors such as cimetidine and famotidine can alter tizanidine metabolism and bioavailability.
Central nervous system depressants including opioids, benzodiazepines, muscle relaxants, and anticonvulsants can cause additive sedation and respiratory depression.
Drugs like ticlopidine and zileuton that affect hepatic enzymes may modify tizanidine clearance.
Hormonal contraceptives may interact through hepatic enzyme modulation affecting tizanidine levels.
Polypharmacy with other sedatives requires caution due to overlapping adverse effect profiles.
Co-administration with other muscle relaxants increases risk of CNS depression and hypotension.
Alcohol consumption potentiates adverse CNS effects and should be avoided during tizanidine therapy.
Drugs causing hypotension or bradycardia should be used cautiously in combination to avoid hemodynamic instability.
Agents that modulate CYP1A2 levels can unpredictably increase or decrease tizanidine efficacy and safety.
Careful monitoring is essential when initiating or discontinuing interacting medications.

Preparations Of The Drug

Zanaflex tablets available in 2 mg and 4 mg strengths for oral administration.
Zanaflex capsules formulated for extended-release although tetrad studies are more limited than tablets.
Ontralfy oral solution offered as 2 mg per 5 mL concentration, enabling precise dose adjustments.
Commercial preparations are designed to optimize bioavailability and patient compliance.
Formulations may vary in excipients affecting absorption rates and adverse effect risk.
Available in prescription-only formulations, requiring accurate dispensing and patient counseling.
Storage conditions: room temperature, protected from moisture and heat to maintain drug stability.
Oral dosage forms require instructions regarding consistent administration with respect to meals.
Packaging includes blister packs or bottles with child-resistant closures to ensure safe use.
Labeling details include dosage regimen, contraindications, side effects, and interaction warnings.
Generic and branded forms are widely accessible in many regions following regulatory approval.
Patient information leaflets accompany preparations describing indications and precautions.
Preparation forms facilitate titration regimens crucial for minimizing adverse effects.
Consistency among preparations ensures predictable pharmacokinetics and therapeutic response.